Hey, all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Eric Christensen.

Thank you so much for listening today. As always, go check out real-life pharmacology.com.

Get your free 31-page PDF on the top 200 drugs. Simply subscribing by email, we'll get you access to that.

We also get you info out when we've got new podcasts and new

information available as well. So please go take advantage of that at real-life pharmacology.com.

All right, the drug of the day today is Bexagliflosen. Brand name of this medication is Brinzavi.

And this is a relatively new medication that was just approved here in 2023.

It is, as you could potentially tell by the ending, if you've got some experience in pharmacology.

It is an SGLT2 inhibitor.

Mechanistically, how does this work?

Okay, if the drug inhibits sodium glucose co-transporter 2.

And what this transporter is responsible for

is that transporter allows the reabsorption of glucose back into the body.

So as you can imagine, that makes blood concentrations of glucose higher.

So by blocking this transporter, we're essentially reducing blood glucose and putting more glucose in the urine.

Now, what would this be beneficial for? Obviously, it probably makes sense if we're going to lower

blood glucose that we're going to use this medication for diabetes. And that currently is the only indication for Bexiglozin.

I believe there are some other studies that are being looked at for other indications,

as in some of the other SGLT2 inhibitors that do have other indications like cardiovascular risk reduction, for example.

Heart failure is another good example there.

But right now, Bexiglofen only has the diabetes indication.

Dosing is straightforward and easy, 20 milligrams once a day,

...